Sandra P. Reyna

4.2k total citations
47 papers, 1.7k citations indexed

About

Sandra P. Reyna is a scholar working on Genetics, Molecular Biology and Surgery. According to data from OpenAlex, Sandra P. Reyna has authored 47 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Genetics, 22 papers in Molecular Biology and 19 papers in Surgery. Recurrent topics in Sandra P. Reyna's work include Neurogenetic and Muscular Disorders Research (39 papers), RNA modifications and cancer (18 papers) and Congenital Anomalies and Fetal Surgery (15 papers). Sandra P. Reyna is often cited by papers focused on Neurogenetic and Muscular Disorders Research (39 papers), RNA modifications and cancer (18 papers) and Congenital Anomalies and Fetal Surgery (15 papers). Sandra P. Reyna collaborates with scholars based in United States, Italy and Canada. Sandra P. Reyna's co-authors include Kathryn J. Swoboda, Charles Scott, Thomas W. Prior, Mark B. Bromberg, Kristin J. Krosschell, John T. Kissel, Thomas O. Crawford, Mary Schroth, Guy D’Anjou and Gyula Acsádi and has published in prestigious journals such as Journal of the American College of Cardiology, PLoS ONE and Neurology.

In The Last Decade

Sandra P. Reyna

44 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sandra P. Reyna United States 19 1.2k 984 725 222 164 47 1.7k
Douglas M. Sproule United States 26 1.2k 0.9× 1.2k 1.2× 721 1.0× 220 1.0× 137 0.8× 65 2.1k
Ching H. Wang United States 11 1.4k 1.2× 1.1k 1.1× 755 1.0× 113 0.5× 172 1.0× 13 1.8k
Katherine Berry United States 14 342 0.3× 750 0.8× 196 0.3× 200 0.9× 163 1.0× 43 1.2k
A Barois France 21 393 0.3× 850 0.9× 325 0.4× 76 0.3× 267 1.6× 75 1.5k
Joseph A. Shrader United States 19 279 0.2× 448 0.5× 250 0.3× 61 0.3× 78 0.5× 38 1.3k
John R. Mytinger United States 14 371 0.3× 517 0.5× 440 0.6× 123 0.6× 55 0.3× 32 1.3k
Imelda Hughes United Kingdom 18 263 0.2× 507 0.5× 143 0.2× 106 0.5× 81 0.5× 29 978
Anita Cairns Australia 14 183 0.1× 328 0.3× 519 0.7× 110 0.5× 119 0.7× 32 1.4k
Elizabeth Wraige United Kingdom 19 143 0.1× 394 0.4× 127 0.2× 86 0.4× 177 1.1× 51 1.2k
Katy Eichinger United States 19 241 0.2× 806 0.8× 98 0.1× 23 0.1× 142 0.9× 46 1.1k

Countries citing papers authored by Sandra P. Reyna

Since Specialization
Citations

This map shows the geographic impact of Sandra P. Reyna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra P. Reyna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra P. Reyna more than expected).

Fields of papers citing papers by Sandra P. Reyna

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra P. Reyna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra P. Reyna. The network helps show where Sandra P. Reyna may publish in the future.

Co-authorship network of co-authors of Sandra P. Reyna

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra P. Reyna. A scholar is included among the top collaborators of Sandra P. Reyna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra P. Reyna. Sandra P. Reyna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tizzano, Eduardo F., Susana Quijano-Roy, Laurent Servais, et al.. (2024). Outcomes for patients in the RESTORE registry with spinal muscular atrophy and four or more SMN2 gene copies treated with onasemnogene abeparvovec. European Journal of Paediatric Neurology. 53. 18–24.
2.
3.
McGrattan, Katlyn, Sally Dunaway Young, Eamonn O’Brien, et al.. (2023). Patients with Spinal Muscular Atrophy Type 1 Achieve and Maintain Bulbar Function Following Onasemnogene Abeparvovec Treatment. Journal of Neuromuscular Diseases. 10(4). 531–540. 15 indexed citations
4.
5.
Chand, Deepa H., et al.. (2022). Safety of Onasemnogene Abeparvovec for Patients With Spinal Muscular Atrophy 8.5 kg or Heavier in a Global Managed Access Program. Pediatric Neurology. 132. 27–32. 17 indexed citations
6.
Day, John, Jerry R. Mendell, Eugenio Mercuri, et al.. (2021). Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy. Drug Safety. 44(10). 1109–1119. 81 indexed citations
7.
Chand, Deepa H., Craig M. Zaidman, Kapil Arya, et al.. (2020). Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series. The Journal of Pediatrics. 231. 265–268. 138 indexed citations
8.
Belter, Lisa, Jill Jarecki, Sandra P. Reyna, et al.. (2020). The Cure SMA Membership Surveys: Highlights of Key Demographic and Clinical Characteristics of Individuals with Spinal Muscular Atrophy. Journal of Neuromuscular Diseases. 8(1). 109–123. 12 indexed citations
9.
10.
Jones, Cynthia C., Suzanne F. Cook, Jill Jarecki, et al.. (2019). Spinal Muscular Atrophy (SMA) Subtype Concordance in Siblings: Findings From the Cure SMA Cohort. Journal of Neuromuscular Diseases. 7(1). 33–40. 15 indexed citations
11.
Shieh, Perry B., Gyula Acsádi, Wolfgang Mueller‐Felber, et al.. (2018). Safety and Efficacy of Nusinersen in Infants/Children with Spinal Muscular Atrophy (SMA): Part 1 of the Phase 2 EMBRACE Study (P2.324). Neurology. 90(15_supplement). 2 indexed citations
12.
Lally, Cathy, Cynthia C. Jones, Wildon Farwell, et al.. (2017). Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States. Orphanet Journal of Rare Diseases. 12(1). 175–175. 63 indexed citations
13.
Smith, A. Gordon, et al.. (2014). The diagnostic utility of Sudoscan for distal symmetric peripheral neuropathy. Journal of Diabetes and its Complications. 28(4). 511–516. 103 indexed citations
14.
Krosschell, Kristin J., Charles Scott, Jo Anne Maczulski, et al.. (2011). Reliability of the modified hammersmith functional motor scale in young children with spinal muscular atrophy. Muscle & Nerve. 44(2). 246–251. 23 indexed citations
15.
Kissel, John T., Charles Scott, Sandra P. Reyna, et al.. (2011). SMA CARNI-VAL TRIAL PART II: A Prospective, Single-Armed Trial of L-Carnitine and Valproic Acid in Ambulatory Children with Spinal Muscular Atrophy. PLoS ONE. 6(7). e21296–e21296. 89 indexed citations
16.
Swoboda, Kathryn J., Charles Scott, Thomas O. Crawford, et al.. (2010). SMA CARNI-VAL Trial Part I: Double-Blind, Randomized, Placebo-Controlled Trial of L-Carnitine and Valproic Acid in Spinal Muscular Atrophy. PLoS ONE. 5(8). e12140–e12140. 124 indexed citations
17.
Swoboda, Kathryn J., Charles Scott, Sandra P. Reyna, et al.. (2009). Phase II Open Label Study of Valproic Acid in Spinal Muscular Atrophy. PLoS ONE. 4(5). e5268–e5268. 132 indexed citations
18.
Ronnow, Brianna S., Sandra P. Reyna, Joseph B. Muhlestein, et al.. (2005). C-Reactive Protein Predicts Death in Patients with Non-Ischemic Cardiomyopathy. Cardiology. 104(4). 196–201. 12 indexed citations
19.
Anderson, Jeffrey L., Benjamin D. Horne, Sandra P. Reyna, et al.. (2004). Which Features of the Metabolic Syndrome Predict the Prevalence and Clinical Outcomes of Angiographic Coronary Artery Disease?. Cardiology. 101(4). 185–193. 56 indexed citations
20.
Maycock, Chloe A. Allen, Donald Lappé, Brian G. Crandall, et al.. (2003). Is atrial fibrillation an inflammatory disease reflected by elevated C-reactive protein?. Journal of the American College of Cardiology. 41(6). 99–99. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Douglas M. Sproule Breakdown of academic impact, for papers by Ching H. Wang Breakdown of academic impact, for papers by Katherine Berry Breakdown of academic impact, for papers by A Barois Breakdown of academic impact, for papers by Joseph A. Shrader Breakdown of academic impact, for papers by John R. Mytinger Breakdown of academic impact, for papers by Imelda Hughes Breakdown of academic impact, for papers by Anita Cairns Breakdown of academic impact, for papers by Elizabeth Wraige Breakdown of academic impact, for papers by Katy Eichinger
Rankless by CCL
2026